Send to

Choose Destination
Medicine (Baltimore). 2014 Dec;93(28):e340. doi: 10.1097/MD.0000000000000340.

Cord blood-derived cytokine-induced killer cellular therapy plus radiation therapy for esophageal cancer: a case report.

Author information

From the Cell Therapy Center (LW, ML, WB, ZZ, YL); Department of Radiation Oncology (SH, YD, HZ), 323 Hospital of Chinese People's Liberation Army, Xi'an; Alliancells Institute of Stem Cells and Translational Regenerative Medicine of Zhongyuan Union Stem Cell Bioengineering Co Ltd (YL), Tianjin, China; Harold Hamm Diabetes Center and Section of Endocrinology and Diabetes in the Department of Internal Medicine (MW), and Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK; and School of Life Sciences and Technology (YL, MW), Tongji University, Shanghai, China.


Esophageal cancer is a serious malignancy with regards to mortality and prognosis. Current treatment options include multimodality therapy mainstays of current treatment including surgery, radiation, and chemotherapy. Cell therapy for esophageal cancer is an advancing area of research. We report a case of esophageal cancer following cord blood-derived cytokine-induced killer cell infusion and adjuvant radiotherapy. Initially, she presented with poor spirit, full liquid diets, and upper abdominal pain. Through cell therapy plus adjuvant radiotherapy, the patient remitted and was self-reliant. Recognition of this curative effect of sequent therapy for esophageal cancer is important to enable appropriate treatment. This case highlights cord blood-derived cytokine-induced killer cell therapy significantly alleviates the adverse reaction of radiation and improves the curative effect. Cell therapy plus adjuvant radiotherapy can be a safe and effective treatment for esophageal cancer.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center